ACHP letter backing H.R. 5526/S. 1954, which would eliminate the separate interchangeability designation for FDA-approved biosimilars, reducing costs and expanding patient access to lower-priced biologic therapies.
ACHP submitted a comment letter to CMS Administrator Oz on the HHS Notice of Benefit and Payment Parameters for 2027, outlining key priorities to strengthen the ACA Marketplace for regional health plans and the 23 million Americans they serve.
ACHP submitted comments to CMS on the CY 2027 Medicare Advantage Advance Notice, urging reforms to risk adjustment, the effective growth rate, USPCC calculations and Star Ratings to support regional health plans and seniors.
ACHP urges HHS to accelerate responsible AI adoption in health care through coordinated federal policy, modernized reimbursement and stronger patient protections.